Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q2 2024 · 10-Q
Revenue$726.40K$726.40K+11.6% vs Q2 2023 Net Income-$1.27M-$1.27MN/M vs Q2 2023 EPS Diluted-$0.83-$0.83N/M vs Q2 2023 Operating Income-$1,337,396N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-184.1%−0.1 pt vs Q2 2023
Net margin-175.4%−13.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end